Check out the companies making headlines before the bell. Hims & Hers Health — Shares tumbled 22%. While the telehealth provider posted a fourth-quarter earnings and revenue beat , it said it would no longer be able to sell compounded versions of weight loss drugs after the first quarter. This comes after the Food and Drug Administration declared weight loss drugs like Wegovy are no longer in shortage, closing a loophole that allowed Hims & Hers to supply the products. Tempus AI — Tempus AI shares slipped 14% after the company’s fourth-quarter revenue fell short of expectations. The company posted revenue of $201 million, which was below the LSEG estimate of $203 million. For 2025, the company expects revenue of $1.24 billion. Eli Lilly — Shares rose 1% after the pharmaceutical company launched higher dose vials of its weight loss drug Zepbound at a lower price for self-pay patients through its direct-to-consumer website. Chegg — Shares of the online education company, which is now worth less than $200 million, plunged roughly 20% after it posted a net loss of $6.1 million on revenue of $143.5 million in the fourth quarter. Revenue was down 24% year over year. Chegg said it sued Google, claiming that the tech company’s artificial intelligence summaries of search results have hurt Chegg’s traffic and revenue. Ke …
